Allogene Therapeutics Ownership 2024 | Who Owns Allogene Therapeutics Now?
Institutional Ownership
97.41%
Insider Ownership
17.48%
Retail Ownership
-14.89%
Institutional Holders
168.00
Allogene Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| FMR LLC | 18.48% | 0.00% | 31,257,600 | 5,893,802 | 23.24% | 72,830,208 | Jun 30, 2024 |
| TPG GP A, LLC | 11.07% | 1.00% | 18,716,306 | - | - | 43,608,993 | Jun 30, 2024 |
| BLACKROCK INC. | 9.72% | 0.00% | 16,445,682 | 6,792,752 | 70.37% | 38,318,438 | Jun 30, 2024 |
| VANGUARD GROUP INC | 4.85% | 0.00% | 8,195,666 | -11,898 | -0.14% | 19,095,902 | Jun 30, 2024 |
| STATE STREET CORP | 4.53% | 0.00% | 7,668,124 | -1,515,887 | -16.51% | 17,866,729,000 | Jun 30, 2024 |
| CAPITAL WORLD INVESTORS | 4.08% | 0.00% | 6,896,552 | 6,896,552 | 100.00% | 16,068,966 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.42% | 0.00% | 5,790,542 | 1,612,923 | 38.61% | 13,493,000 | Jun 30, 2024 |
| PRIMECAP MANAGEMENT CO/CA/ | 3.35% | 0.01% | 5,670,226 | 221,840 | 4.07% | 13,211,627 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 2.58% | 0.10% | 4,358,989 | 1,725,013 | 65.49% | 10,156,444 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 2.44% | 0.00% | 4,124,854 | -1,057,125 | -20.40% | 9,610,910 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 2.28% | 0.47% | 3,850,000 | - | - | 8,970,500 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.75% | 0.02% | 2,960,673 | 1,049,335 | 54.90% | 6,898,368 | Jun 30, 2024 |
| WILDCAT CAPITAL MANAGEMENT, LLC | 1.73% | 1.67% | 2,920,787 | 1,000,000 | 52.06% | 6,805,434 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 1.70% | 0.31% | 2,867,750 | - | - | 6,681,858 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.67% | 0.00% | 2,820,034 | 448,700 | 18.92% | 6,571,727 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 1.61% | 0.15% | 2,725,000 | 2,725,000 | 100.00% | 6,349,250 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 1.51% | 0.00% | 2,550,640 | 507,021 | 24.81% | 5,944,221 | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 1.32% | 1.88% | 2,228,295 | 2,228,295 | 100.00% | 5,191,927 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.30% | 0.38% | 2,200,000 | 850,000 | 62.96% | 5,126,000 | Jun 30, 2024 |
| MORGAN STANLEY | 1.28% | 0.00% | 2,156,962 | -75,002 | -3.36% | 5,025,720 | Jun 30, 2024 |
Allogene Therapeutics's largest institutional shareholder is FMR LLC, holding 18.48% of the company's total share outstanding, currently valued at $72.83M. The top 10 institutional shareholders own together 64.52% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VIDA VENTURES ADVISORS, LLC | 1.06% | 4.58% | 1,798,163 | - | - | 4,189,720 | Jun 30, 2024 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.41% | 2.03% | 689,912 | 168,663 | 32.36% | 1,607,495 | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 1.32% | 1.88% | 2,228,295 | 2,228,295 | 100.00% | 5,191,927 | Jun 30, 2024 |
| WILDCAT CAPITAL MANAGEMENT, LLC | 1.73% | 1.67% | 2,920,787 | 1,000,000 | 52.06% | 6,805,434 | Jun 30, 2024 |
| TPG GP A, LLC | 11.07% | 1.00% | 18,716,306 | - | - | 43,608,993 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 2.28% | 0.47% | 3,850,000 | - | - | 8,970,500 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.30% | 0.38% | 2,200,000 | 850,000 | 62.96% | 5,126,000 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 0.36% | 0.34% | 605,100 | 605,100 | 100.00% | 1,409,883 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 1.70% | 0.31% | 2,867,750 | - | - | 6,681,858 | Jun 30, 2024 |
| COASTAL BRIDGE ADVISORS, LLC | 0.24% | 0.24% | 406,847 | - | - | 947,954 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 1.61% | 0.15% | 2,725,000 | 2,725,000 | 100.00% | 6,349,250 | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.49% | 0.14% | 835,342 | 835,342 | 100.00% | 1,946,000 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 2.58% | 0.10% | 4,358,989 | 1,725,013 | 65.49% | 10,156,444 | Jun 30, 2024 |
| PENNANT INVESTORS, LP | 0.08% | 0.08% | 128,400 | - | - | 299,172 | Jun 30, 2024 |
| BOURGEON CAPITAL MANAGEMENT LLC | 0.08% | 0.06% | 132,455 | 75,255 | 131.56% | 308,621 | Jun 30, 2024 |
| NAVALIGN, LLC | 0.04% | 0.06% | 75,365 | - | - | 175,600 | Jun 30, 2024 |
| VIRTUS ETF ADVISERS LLC | 0.02% | 0.04% | 35,640 | 3,673 | 11.49% | 83,041 | Jun 30, 2024 |
| CAXTON ASSOCIATES LP | 0.28% | 0.04% | 466,110 | 34,924 | 8.10% | 1,086,036 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.04% | 0.02% | 63,470 | -633 | -0.99% | 147,885 | Jun 30, 2024 |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 0.25% | 0.02% | 418,699 | 132,291 | 46.19% | 975,569 | Jun 30, 2024 |
The largest Allogene Therapeutics shareholder by % of total assets is VIDA VENTURES ADVISORS, LLC. The company owns 1.80M shares of Allogene Therapeutics (ALLO), representing 4.58% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CAPITAL WORLD INVESTORS | 4.08% | 0.00% | 6,896,552 | 6,896,552 | 100.00% | 16,068,966 | Jun 30, 2024 |
| BLACKROCK INC. | 9.72% | 0.00% | 16,445,682 | 6,792,752 | 70.37% | 38,318,438 | Jun 30, 2024 |
| FMR LLC | 18.48% | 0.00% | 31,257,600 | 5,893,802 | 23.24% | 72,830,208 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 1.61% | 0.15% | 2,725,000 | 2,725,000 | 100.00% | 6,349,250 | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 1.32% | 1.88% | 2,228,295 | 2,228,295 | 100.00% | 5,191,927 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 2.58% | 0.10% | 4,358,989 | 1,725,013 | 65.49% | 10,156,444 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.42% | 0.00% | 5,790,542 | 1,612,923 | 38.61% | 13,493,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.03% | 0.01% | 1,747,955 | 1,351,055 | 340.40% | 4,072,735 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.75% | 0.02% | 2,960,673 | 1,049,335 | 54.90% | 6,898,368 | Jun 30, 2024 |
| WILDCAT CAPITAL MANAGEMENT, LLC | 1.73% | 1.67% | 2,920,787 | 1,000,000 | 52.06% | 6,805,434 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.52% | 0.01% | 878,955 | 878,955 | 100.00% | 2,047,965 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 1.30% | 0.38% | 2,200,000 | 850,000 | 62.96% | 5,126,000 | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.49% | 0.14% | 835,342 | 835,342 | 100.00% | 1,946,000 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 0.36% | 0.34% | 605,100 | 605,100 | 100.00% | 1,409,883 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 1.51% | 0.00% | 2,550,640 | 507,021 | 24.81% | 5,944,221 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.67% | 0.00% | 2,820,034 | 448,700 | 18.92% | 6,571,727 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.47% | 0.00% | 799,340 | 361,904 | 82.73% | 1,862,462 | Jun 30, 2024 |
| PARTNERS CAPITAL INVESTMENT GROUP, LLP | 0.27% | 0.02% | 454,845 | 361,597 | 387.78% | 1,070,046 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.70% | 0.00% | 1,178,401 | 319,925 | 37.27% | 2,745,674 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.16% | 0.00% | 264,329 | 264,329 | 100.00% | 617,614 | Jun 30, 2024 |
As of Jun 30 2024, Allogene Therapeutics's largest institutional buyer is CAPITAL WORLD INVESTORS. The company purchased 6.90M stocks of ALLO, valued at $16.07M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 4.53% | 0.00% | 7,668,124 | -1,515,887 | -16.51% | 17,866,729,000 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 2.44% | 0.00% | 4,124,854 | -1,057,125 | -20.40% | 9,610,910 | Jun 30, 2024 |
| OCTAGON CAPITAL ADVISORS LP | - | - | - | -720,000 | -100.00% | - | Jun 30, 2024 |
| ZACKS INVESTMENT MANAGEMENT | - | - | - | -459,800 | -100.00% | - | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.35% | 0.01% | 584,840 | -405,863 | -40.97% | 1,362,677 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.00% | 0.00% | 6,233 | -355,680 | -98.28% | 15,209 | Jun 30, 2024 |
| UBS GROUP AG | 0.18% | 0.00% | 300,321 | -218,880 | -42.16% | 699,748 | Jun 30, 2024 |
| NEBULA RESEARCH & DEVELOPMENT LLC | - | - | - | -115,988 | -100.00% | - | Jun 30, 2024 |
| NORDEA INVESTMENT MANAGEMENT AB | 0.38% | 0.00% | 634,660 | -107,454 | -14.48% | 1,475,585 | Jun 30, 2024 |
| SHERBROOKE PARK ADVISERS LLC | - | - | - | -107,398 | -100.00% | - | Jun 30, 2024 |
| PDT PARTNERS, LLC | 0.05% | 0.02% | 85,610 | -103,418 | -54.71% | 199,471 | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -96,837 | -100.00% | - | Jun 30, 2024 |
| MORGAN STANLEY | 1.28% | 0.00% | 2,156,962 | -75,002 | -3.36% | 5,025,720 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.14% | 0.00% | 239,069 | -63,186 | -20.90% | 557,031 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.00% | - | 444 | -58,480 | -99.25% | 1,035,000 | Jun 30, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | 0.00% | - | 7,229 | -52,591 | -87.92% | 16,844 | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -46,567 | -100.00% | - | Jun 30, 2024 |
| PROFUND ADVISORS LLC | 0.04% | 0.01% | 76,160 | -44,899 | -37.09% | 177,453 | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -35,765 | -100.00% | - | Jun 30, 2024 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 0.07% | 0.00% | 125,030 | -35,593 | -22.16% | 291,320 | Jun 30, 2024 |
As of Jun 30 2024, Allogene Therapeutics's biggest institutional seller is STATE STREET CORP. The company sold -1.52M shares of ALLO, valued at $17.87B.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CAPITAL WORLD INVESTORS | 4.08% | 0.00% | 6,896,552 | 6,896,552 | 100.00% | 16,068,966 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 1.61% | 0.15% | 2,725,000 | 2,725,000 | 100.00% | 6,349,250 | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 1.32% | 1.88% | 2,228,295 | 2,228,295 | 100.00% | 5,191,927 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.52% | 0.01% | 878,955 | 878,955 | 100.00% | 2,047,965 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 0.36% | 0.34% | 605,100 | 605,100 | 100.00% | 1,409,883 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.16% | 0.00% | 264,329 | 264,329 | 100.00% | 617,614 | Jun 30, 2024 |
| TOROSO INVESTMENTS, LLC | 0.14% | 0.01% | 236,536 | 236,536 | 100.00% | 551,128 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.07% | 0.00% | 126,628 | 126,628 | 100.00% | 295,043 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.05% | 0.00% | 80,197 | 80,197 | 100.00% | 186,859 | Jun 30, 2024 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 0.03% | 0.00% | 57,300 | 57,300 | 100.00% | 133,509 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 56,578 | 56,578 | 100.00% | 131,827 | Jun 30, 2024 |
| BAYESIAN CAPITAL MANAGEMENT, LP | 0.02% | 0.01% | 35,402 | 35,402 | 100.00% | 82,487 | Jun 30, 2024 |
| AQR CAPITAL MANAGEMENT LLC | 0.02% | 0.00% | 27,287 | 27,287 | 100.00% | 63,579 | Jun 30, 2024 |
| ALGERT GLOBAL LLC | 0.01% | 0.00% | 14,808 | 14,808 | 100.00% | 35,000 | Jun 30, 2024 |
| DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 0.01% | 0.00% | 14,085 | 14,085 | 100.00% | 33,000 | Jun 30, 2024 |
| PHOENIX WEALTH ADVISORS | 0.01% | 0.02% | 13,000 | 13,000 | 100.00% | 30,290 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 0.01% | 0.00% | 12,300 | 12,300 | 100.00% | 28,659,000 | Jun 30, 2024 |
| ATOM INVESTORS LP | 0.01% | 0.00% | 10,833 | 10,833 | 100.00% | 25,241 | Jun 30, 2024 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 0.01% | 0.00% | 10,399 | 10,399 | 100.00% | 24,230 | Jun 30, 2024 |
| AMUNDI | 0.00% | - | 8,011 | 8,011 | 100.00% | 16,663 | Jun 30, 2024 |
| CULLEN/FROST BANKERS, INC. | 0.00% | - | 1,315 | 1,315 | 100.00% | 3,064 | Jun 30, 2024 |
| NORDWAND ADVISORS, LLC | 0.00% | 0.00% | 1,000 | 1,000 | 100.00% | 2,330 | Jun 30, 2024 |
| ABICH FINANCIAL WEALTH MANAGEMENT LLC | 0.00% | 0.00% | 283 | 283 | 100.00% | 659 | Jun 30, 2024 |
| WEST OAK CAPITAL, LLC | 0.00% | 0.00% | 100 | 100 | 100.00% | 233 | Jun 30, 2024 |
Allogene Therapeutics's largest new institutional shareholder by number of shares is CAPITAL WORLD INVESTORS, purchased 6.90M shares, valued at $16.07M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OCTAGON CAPITAL ADVISORS LP | - | - | - | -720,000 | -100.00% | - | Jun 30, 2024 |
| ZACKS INVESTMENT MANAGEMENT | - | - | - | -459,800 | -100.00% | - | Jun 30, 2024 |
| NEBULA RESEARCH & DEVELOPMENT LLC | - | - | - | -115,988 | -100.00% | - | Jun 30, 2024 |
| SHERBROOKE PARK ADVISERS LLC | - | - | - | -107,398 | -100.00% | - | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -96,837 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -46,567 | -100.00% | - | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -35,765 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -29,815 | -100.00% | - | Jun 30, 2024 |
| HEADLANDS TECHNOLOGIES LLC | - | - | - | -17,396 | -100.00% | - | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -3,861 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -3,664 | -100.00% | - | Jun 30, 2024 |
| QUADRANT CAPITAL GROUP LLC | - | - | - | -1,414 | -100.00% | - | Jun 30, 2024 |
| OLD POINT TRUST & FINANCIAL SERVICES N A | - | - | - | -500 | -100.00% | - | Jun 30, 2024 |
| NBC SECURITIES, INC. | - | - | - | -200 | -100.00% | - | Jun 30, 2024 |
| WESTEND CAPITAL MANAGEMENT, LLC | - | - | - | -175 | -100.00% | - | Jun 30, 2024 |
| PRIVATE WEALTH MANAGEMENT GROUP, LLC | - | - | - | -140 | -100.00% | - | Jun 30, 2024 |
Allogene Therapeutics's largest sold out institutional shareholder by shares sold is OCTAGON CAPITAL ADVISORS LP, sold -0.72M shares, valued at -, as of undefined.
Allogene Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Kelly Strategic ETF Trust | 1.22% | 32,998 | - | - | Feb 29, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.86% | 2,870,342 | 1,549,646 | 117.34% | Mar 31, 2024 |
| NEW ECONOMY FUND | 0.43% | 1,937,892 | - | - | Feb 29, 2024 |
| LORD ABBETT DEVELOPING GROWTH FUND, INC. | 0.41% | 380,807 | - | - | Jan 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.40% | 3,410,455 | 9,000 | 0.26% | Jan 31, 2024 |
| Zacks Trust | 0.36% | 32,751 | 32,751 | - | Feb 29, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.34% | 1,678,192 | - | - | Mar 31, 2024 |
| SARATOGA ADVANTAGE TRUST | 0.33% | 20,206 | 20,206 | - | Feb 29, 2024 |
| PRIMECAP Odyssey Funds | 0.23% | 1,881,671 | 67,400 | 3.71% | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND IV | 0.22% | 600,000 | - | - | Mar 31, 2024 |
| Nuveen NASDAQ 100 Dynamic Overwrite Fund | 0.22% | 26,050 | - | - | Mar 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.14% | 4,121,552 | -65,881 | -1.57% | Feb 29, 2024 |
| VANGUARD HORIZON FUNDS | 0.14% | 3,393,879 | 16,000 | 0.47% | Mar 31, 2024 |
| RMB INVESTORS TRUST | 0.14% | 73,815 | 627 | 0.86% | Dec 31, 2023 |
| DELAWARE GROUP EQUITY FUNDS IV | 0.13% | 146,779 | - | - | Mar 28, 2024 |
| BlackRock Health Sciences Trust | 0.12% | 30,670 | - | - | Mar 31, 2024 |
| EntrepreneurShares Series Trust | 0.12% | 32,059 | - | - | Dec 31, 2023 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.11% | 365,301 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.10% | 6,277,888 | - | - | Feb 29, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.09% | 47,833 | - | - | Mar 31, 2024 |
| Federated Hermes MDT Series | 0.09% | 210,080 | - | - | Jan 31, 2024 |
| Humankind Benefit Corp | 0.08% | 1,745 | 415 | 31.20% | Dec 31, 2023 |
| SMALLCAP WORLD FUND INC | 0.08% | 5,310,109 | - | - | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.07% | 121,946 | 58,800 | 93.12% | Mar 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.06% | 719,605 | 4,500 | 0.63% | Jan 31, 2024 |
| BlackRock Health Sciences Trust II | 0.05% | 137,796 | - | - | Mar 31, 2024 |
| RENAISSANCE CAPITAL GREENWICH FUNDS | 0.05% | 37,164 | - | - | Mar 31, 2024 |
| VICTORY VARIABLE INSURANCE FUNDS | 0.05% | 23,790 | - | - | Mar 31, 2024 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.04% | 161,365 | - | - | Mar 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.04% | 7,902 | - | - | Mar 28, 2024 |
| FIDELITY SECURITIES FUND | 0.04% | 3,604,600 | 4,500 | 0.12% | Jan 31, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.04% | 326,797 | - | - | Jan 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.04% | 32,954 | - | - | Mar 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.03% | 15,135 | - | - | Mar 31, 2024 |
| AB CAP FUND, INC. | 0.03% | 1,010,135 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.03% | 14,837 | - | - | Mar 31, 2024 |
| AMERICAN CENTURY GROWTH FUNDS, INC. | 0.02% | 3,725 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.02% | 146,910 | - | - | Mar 31, 2024 |
| GROWTH FUND OF AMERICA | 0.02% | 582,615 | - | - | Feb 29, 2024 |
| ETFis Series Trust I | 0.02% | 30,282 | 10,447 | 52.67% | Jan 31, 2024 |
| Fidelity Central Investment Portfolios LLC | 0.02% | 1,000,000 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.02% | 7,099,543 | -2,699,006 | -27.54% | Mar 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.02% | 52,395 | - | - | Feb 29, 2024 |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 0.01% | 293,993 | - | - | Mar 31, 2024 |
| Nushares ETF Trust | 0.01% | 95,467 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND | 0.01% | 275,000 | - | - | Mar 31, 2024 |
| Calvert Responsible Index Series, Inc. | 0.01% | 21,093 | - | - | Mar 31, 2024 |
| FIDELITY CONTRAFUND | 0.01% | 810,218 | - | - | Mar 31, 2024 |
| UBS FUNDS | 0.01% | 54,781 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 2,417 | - | - | Mar 31, 2024 |
| ALPS ETF Trust | 0.01% | 128,094 | 9,685 | 8.18% | Feb 29, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.01% | 104,549 | - | - | Mar 31, 2024 |
| Bernstein Fund Inc | 0.01% | 67,631 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.01% | 269,357 | 40,161 | 17.52% | Jan 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.01% | 23,600 | - | - | Jan 31, 2024 |
| Fidelity Commonwealth Trust II | 0.01% | 40,603 | - | - | Aug 31, 2023 |
| BNY Mellon Strategic Funds, Inc. | 0.01% | 11,996 | - | - | Mar 31, 2024 |
| Simplify Exchange Traded Funds | 0.00% | 245,000 | - | - | Mar 31, 2024 |
| Harbor ETF Trust | 0.00% | 21,763 | -1,422 | -6.13% | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 950,536 | -138,520 | -12.72% | Feb 29, 2024 |
| Listed Funds Trust | 0.00% | 19,194 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 714,800 | 2,400 | 0.34% | Feb 29, 2024 |
| AB VARIABLE PRODUCTS SERIES FUND, INC. | 0.00% | 16,551 | - | - | Mar 31, 2024 |
| John Hancock Exchange-Traded Fund Trust | 0.00% | 21,581 | - | - | Jan 31, 2024 |
| ProFunds | 0.00% | 40,625 | 39,830 | 5010.06% | Mar 31, 2024 |
| JNL VARIABLE FUND LLC | 0.00% | 19,042 | - | - | Mar 31, 2020 |
| MORGAN STANLEY INSTITUTIONAL FUND INC | 0.00% | 224,039 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 56,921 | 11,583 | 25.55% | Jan 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 8,104 | - | - | Mar 31, 2024 |
| VANGUARD EXPLORER FUND | 0.00% | 35,132 | - | - | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 69,884 | -5,294 | -7.04% | Mar 31, 2024 |
| HARBOR FUNDS | 0.00% | 51,149 | -3,625 | -6.62% | Jan 31, 2024 |
| BLACKROCK ADVANTAGE GLOBAL FUND, INC. | 0.00% | 650 | - | - | Mar 31, 2024 |
| VANGUARD WHITEHALL FUNDS | 0.00% | 202,100 | - | - | Jan 31, 2024 |
| JPMORGAN TRUST II | 0.00% | 2,138,882 | - | - | Feb 29, 2024 |
| Thrivent Core Funds | 0.00% | 127,491 | - | - | Jan 31, 2024 |
| CAPITAL GROUP PRIVATE CLIENT SERVICES FUNDS | 0.00% | 13,100 | - | - | Jan 31, 2024 |
| ETF Series Solutions | 0.00% | 42,403 | 6,795 | 19.08% | Feb 29, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 19,685 | -3,031 | -13.34% | Mar 31, 2024 |
| Dimensional ETF Trust | 0.00% | 715,230 | -48,952 | -6.41% | Jan 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 394,395 | 74,639 | 23.34% | Feb 29, 2024 |
| Direxion Shares ETF Trust | 0.00% | 220,281 | -516,706 | -70.11% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 417,294 | -13,348 | -3.10% | Feb 29, 2024 |
| TARGET PORTFOLIO TRUST | 0.00% | 27,600 | - | - | Jan 31, 2024 |
| Managed Portfolio Series | 0.00% | 28,533 | - | - | Mar 31, 2024 |
| VICTORY PORTFOLIOS | 0.00% | 31,860 | - | - | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 593,578 | 33,858 | 6.05% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 31,412 | -6,935 | -18.08% | Mar 31, 2024 |
| OHIO NATIONAL FUND INC | 0.00% | 18,877 | - | - | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 4,225 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 445 | - | - | Apr 30, 2021 |
| NUVEEN INVESTMENT FUNDS INC | 0.00% | 28,411 | - | - | Jan 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 67,967 | 66 | 0.10% | Jan 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 86,865 | 23,345 | 36.75% | Feb 29, 2024 |
| Voya INVESTORS TRUST | 0.00% | 41,180 | -3,051 | -6.90% | Mar 31, 2024 |
| PFM Multi-Manager Series Trust | 0.00% | 600 | - | - | Dec 31, 2023 |
| VALIC Co II | 0.00% | 24,581 | 1,096 | 4.67% | Feb 28, 2021 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 2,970 | - | - | Mar 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 78,659 | - | - | Mar 28, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 8,682 | -418 | -4.59% | Mar 31, 2023 |
Allogene Therapeutics's largest mutual fund holder by % of total assets is "Kelly Strategic ETF Trust", owning 33.00K shares, compromising 1.22% of its total assets.
Allogene Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 168 | 5.66% |
| 31 Mar, 24 | 159 | -5.92% |
| 31 Dec, 23 | 169 | 11.92% |
| 30 Sep, 23 | 151 | -10.65% |
| 30 Jun, 23 | 169 | -5.06% |
| 31 Mar, 23 | 178 | 6.59% |
| 31 Dec, 22 | 167 | -11.64% |
| 30 Sep, 22 | 189 | 18.13% |
| 30 Jun, 22 | 160 | -13.04% |
| 31 Mar, 22 | 184 | 3.95% |
| 31 Dec, 21 | 177 | 2.91% |
| 30 Sep, 21 | 172 | -9.95% |
| 30 Jun, 21 | 191 | 8.52% |
| 31 Mar, 21 | 176 | 6.02% |
| 31 Dec, 20 | 166 | -1.78% |
| 30 Sep, 20 | 169 | -9.14% |
| 30 Jun, 20 | 186 | 55.00% |
| 31 Mar, 20 | 120 | -1.64% |
| 31 Dec, 19 | 122 | 18.45% |
| 30 Sep, 19 | 103 | 6.19% |
| 30 Jun, 19 | 97 | 7.78% |
| 31 Mar, 19 | 90 | 11.11% |
| 31 Dec, 18 | 81 | - |
| 31 Mar, 16 | 1 | - |
As of 30 Jun 24, 168 institutions are holding Allogene Therapeutics's shares, representing an increase of 5.66% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 164,749,732 | 25.63% |
| 31 Mar, 24 | 131,135,320 | 7.91% |
| 31 Dec, 23 | 121,517,475 | -5.63% |
| 30 Sep, 23 | 128,760,668 | -2.59% |
| 30 Jun, 23 | 132,189,252 | 13.33% |
| 31 Mar, 23 | 116,639,365 | 5.24% |
| 31 Dec, 22 | 110,832,498 | 4.43% |
| 30 Sep, 22 | 106,129,414 | 5.33% |
| 30 Jun, 22 | 100,762,246 | 9.87% |
| 31 Mar, 22 | 91,707,002 | 6.92% |
| 31 Dec, 21 | 85,772,925 | -2.46% |
| 30 Sep, 21 | 87,938,222 | 1.89% |
| 30 Jun, 21 | 86,306,760 | -2.27% |
| 31 Mar, 21 | 88,306,988 | -1.14% |
| 31 Dec, 20 | 89,327,420 | 5.16% |
| 30 Sep, 20 | 84,943,555 | -4.23% |
| 30 Jun, 20 | 88,695,151 | 20.33% |
| 31 Mar, 20 | 73,707,111 | 2.91% |
| 31 Dec, 19 | 71,621,399 | 4.26% |
| 30 Sep, 19 | 68,694,100 | -0.27% |
| 30 Jun, 19 | 68,882,280 | 5.34% |
| 31 Mar, 19 | 65,390,669 | 4.33% |
| 31 Dec, 18 | 62,679,454 | - |
| 31 Mar, 16 | 4,033 | - |
Allogene Therapeutics (ALLO) has 164.75M shares outstanding as of 30 Jun 24, up 25.63% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 97.41% | 1.62% |
| 31 Mar, 24 | 77.54% | 1.49% |
| 31 Dec, 23 | 72.19% | 1.22% |
| 30 Sep, 23 | 76.80% | 0.95% |
| 30 Jun, 23 | 90.05% | 1.38% |
| 31 Mar, 23 | 80.68% | 1.35% |
| 31 Dec, 22 | 77.43% | 1.42% |
| 30 Sep, 22 | 73.87% | 1.50% |
| 30 Jun, 22 | 70.27% | 1.67% |
| 31 Mar, 22 | 64.88% | 1.71% |
| 31 Dec, 21 | 61.63% | 1.50% |
| 30 Sep, 21 | 64.18% | 1.57% |
| 30 Jun, 21 | 64.01% | 1.43% |
| 31 Mar, 21 | 66.87% | 1.41% |
| 31 Dec, 20 | 68.80% | 1.54% |
| 30 Sep, 20 | 66.81% | 1.13% |
| 30 Jun, 20 | 76.87% | 1.68% |
| 31 Mar, 20 | 67.64% | 1.35% |
| 31 Dec, 19 | 70.87% | 1.57% |
| 30 Sep, 19 | 67.22% | 1.41% |
| 30 Jun, 19 | 68.99% | 1.53% |
| 31 Mar, 19 | 67.19% | 1.15% |
| 31 Dec, 18 | 76.38% | - |
| 31 Mar, 16 | 0.00% | - |
As of 30 Jun 24, Allogene Therapeutics is held by 97.41% institutional shareholders, representing a 1.62% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 94 | 23.68% |
| 31 Mar, 24 | 76 | -15.56% |
| 31 Dec, 23 | 90 | 9.76% |
| 30 Sep, 23 | 82 | 2.50% |
| 30 Jun, 23 | 80 | -11.11% |
| 31 Mar, 23 | 90 | 2.27% |
| 31 Dec, 22 | 88 | -11.11% |
| 30 Sep, 22 | 99 | 28.57% |
| 30 Jun, 22 | 77 | -24.51% |
| 31 Mar, 22 | 102 | -0.97% |
| 31 Dec, 21 | 103 | 45.07% |
| 30 Sep, 21 | 71 | -41.80% |
| 30 Jun, 21 | 122 | 50.62% |
| 31 Mar, 21 | 81 | -12.90% |
| 31 Dec, 20 | 93 | 10.71% |
| 30 Sep, 20 | 84 | -32.26% |
| 30 Jun, 20 | 124 | 121.43% |
| 31 Mar, 20 | 56 | -17.65% |
| 31 Dec, 19 | 68 | 33.33% |
| 30 Sep, 19 | 51 | -17.74% |
| 30 Jun, 19 | 62 | 29.17% |
| 31 Mar, 19 | 48 | -40.00% |
| 31 Dec, 18 | 80 | - |
| 31 Mar, 16 | 1 | - |
94 institutional shareholders have increased their position in ALLO stock as of 30 Jun 24 compared to 76 in the previous quarter (a 23.68% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 41 | -4.65% |
| 31 Mar, 24 | 43 | -14.00% |
| 31 Dec, 23 | 50 | 47.06% |
| 30 Sep, 23 | 34 | -34.62% |
| 30 Jun, 23 | 52 | 4.00% |
| 31 Mar, 23 | 50 | 2.04% |
| 31 Dec, 22 | 49 | -3.92% |
| 30 Sep, 22 | 51 | 4.08% |
| 30 Jun, 22 | 49 | 11.36% |
| 31 Mar, 22 | 44 | 4.76% |
| 31 Dec, 21 | 42 | -25.00% |
| 30 Sep, 21 | 56 | 75.00% |
| 30 Jun, 21 | 32 | -48.39% |
| 31 Mar, 21 | 62 | 44.19% |
| 31 Dec, 20 | 43 | -21.82% |
| 30 Sep, 20 | 55 | 44.74% |
| 30 Jun, 20 | 38 | 5.56% |
| 31 Mar, 20 | 36 | 24.14% |
| 31 Dec, 19 | 29 | 20.83% |
| 30 Sep, 19 | 24 | 14.29% |
| 30 Jun, 19 | 21 | 5.00% |
| 31 Mar, 19 | 20 | - |
| 31 Dec, 18 | - | - |
| 31 Mar, 16 | - | - |
41 institutional shareholders have reduced their position in ALLO stock as of 30 Jun 24 compared to 43 in the previous quarter (a -4.65% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 168 | 5.66% | 164,749,732 | 25.63% | 97.41% | 1.62% | 94 | 23.68% | 41 | -4.65% |
| 31 Mar, 24 | 159 | -5.92% | 131,135,320 | 7.91% | 77.54% | 1.49% | 76 | -15.56% | 43 | -14.00% |
| 31 Dec, 23 | 169 | 11.92% | 121,517,475 | -5.63% | 72.19% | 1.22% | 90 | 9.76% | 50 | 47.06% |
| 30 Sep, 23 | 151 | -10.65% | 128,760,668 | -2.59% | 76.80% | 0.95% | 82 | 2.50% | 34 | -34.62% |
| 30 Jun, 23 | 169 | -5.06% | 132,189,252 | 13.33% | 90.05% | 1.38% | 80 | -11.11% | 52 | 4.00% |
| 31 Mar, 23 | 178 | 6.59% | 116,639,365 | 5.24% | 80.68% | 1.35% | 90 | 2.27% | 50 | 2.04% |
| 31 Dec, 22 | 167 | -11.64% | 110,832,498 | 4.43% | 77.43% | 1.42% | 88 | -11.11% | 49 | -3.92% |
| 30 Sep, 22 | 189 | 18.13% | 106,129,414 | 5.33% | 73.87% | 1.50% | 99 | 28.57% | 51 | 4.08% |
| 30 Jun, 22 | 160 | -13.04% | 100,762,246 | 9.87% | 70.27% | 1.67% | 77 | -24.51% | 49 | 11.36% |
| 31 Mar, 22 | 184 | 3.95% | 91,707,002 | 6.92% | 64.88% | 1.71% | 102 | -0.97% | 44 | 4.76% |
| 31 Dec, 21 | 177 | 2.91% | 85,772,925 | -2.46% | 61.63% | 1.50% | 103 | 45.07% | 42 | -25.00% |
| 30 Sep, 21 | 172 | -9.95% | 87,938,222 | 1.89% | 64.18% | 1.57% | 71 | -41.80% | 56 | 75.00% |
| 30 Jun, 21 | 191 | 8.52% | 86,306,760 | -2.27% | 64.01% | 1.43% | 122 | 50.62% | 32 | -48.39% |
| 31 Mar, 21 | 176 | 6.02% | 88,306,988 | -1.14% | 66.87% | 1.41% | 81 | -12.90% | 62 | 44.19% |
| 31 Dec, 20 | 166 | -1.78% | 89,327,420 | 5.16% | 68.80% | 1.54% | 93 | 10.71% | 43 | -21.82% |
| 30 Sep, 20 | 169 | -9.14% | 84,943,555 | -4.23% | 66.81% | 1.13% | 84 | -32.26% | 55 | 44.74% |
| 30 Jun, 20 | 186 | 55.00% | 88,695,151 | 20.33% | 76.87% | 1.68% | 124 | 121.43% | 38 | 5.56% |
| 31 Mar, 20 | 120 | -1.64% | 73,707,111 | 2.91% | 67.64% | 1.35% | 56 | -17.65% | 36 | 24.14% |
| 31 Dec, 19 | 122 | 18.45% | 71,621,399 | 4.26% | 70.87% | 1.57% | 68 | 33.33% | 29 | 20.83% |
| 30 Sep, 19 | 103 | 6.19% | 68,694,100 | -0.27% | 67.22% | 1.41% | 51 | -17.74% | 24 | 14.29% |
| 30 Jun, 19 | 97 | 7.78% | 68,882,280 | 5.34% | 68.99% | 1.53% | 62 | 29.17% | 21 | 5.00% |
| 31 Mar, 19 | 90 | 11.11% | 65,390,669 | 4.33% | 67.19% | 1.15% | 48 | -40.00% | 20 | - |
| 31 Dec, 18 | 81 | - | 62,679,454 | - | 76.38% | - | 80 | - | - | - |
| 31 Mar, 16 | 1 | - | 4,033 | - | 0.00% | - | 1 | - | - | - |
Allogene Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Allogene Therapeutics's stock was made by MESSEMER DEBORAH M. on Jun 20 2024, selling 18,641 shares at $2.28 per share (valued at $42.49K). The last insider buy of ALLO was made by Belldegrun Arie on May 20 2024, buying 1,724,137 shares at $2.90 per share (worth $5.00M).
Allogene Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 13 | 5 | 260.00% |
| Q1 2024 | 13 | 2 | 650.00% |
| Q4 2023 | 3 | 1 | 300.00% |
| Q3 2023 | 5 | 6 | 83.33% |
| Q2 2023 | 11 | 5 | 220.00% |
| Q1 2023 | 11 | 6 | 183.33% |
| Q4 2022 | 1 | 3 | 33.33% |
| Q3 2022 | 1 | 4 | 25.00% |
| Q2 2022 | 10 | 3 | 333.33% |
| Q1 2022 | 14 | 9 | 155.56% |
| Q4 2021 | - | 1 | - |
| Q3 2021 | 6 | 11 | 54.55% |
| Q2 2021 | 12 | 14 | 85.71% |
| Q1 2021 | 13 | 13 | 100.00% |
| Q4 2020 | 9 | 25 | 36.00% |
| Q3 2020 | 4 | 15 | 26.67% |
| Q2 2020 | 11 | 21 | 52.38% |
| Q1 2020 | 13 | 6 | 216.67% |
| Q4 2019 | 6 | 1 | 600.00% |
| Q3 2019 | 25 | 18 | 138.89% |
13 total buy trades, and 5 total sell trades (buy/sell ratio of 2.60%) were made by Allogene Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 1 | 2 | 50.00% |
| Q1 2024 | 1 | - | - |
| Q4 2023 | - | 1 | - |
| Q3 2023 | - | 1 | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | 2 | - |
| Q4 2022 | - | 1 | - |
| Q3 2022 | - | 4 | - |
| Q2 2022 | - | 3 | - |
| Q1 2022 | 2 | 5 | 40.00% |
| Q4 2021 | - | 1 | - |
| Q3 2021 | - | 6 | - |
| Q2 2021 | - | 6 | - |
| Q1 2021 | - | 12 | - |
| Q4 2020 | - | 17 | - |
| Q3 2020 | - | 11 | - |
| Q2 2020 | 2 | 17 | 11.76% |
| Q1 2020 | - | 5 | - |
| Q4 2019 | - | - | - |
| Q3 2019 | - | 9 | - |
As of Q2 2024, Insider owners conducted 1 open market buy trades and 2 open market sell trades of Allogene Therapeutics's stocks.
Allogene Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| VECT | VectivBio Holding AG |
| BPMC | Blueprint Medicines Corporation |
| IPSC | Century Therapeutics, Inc. |
| NTLA | Intellia Therapeutics, Inc. |
| EDIT | Editas Medicine, Inc. |
| PRME | Prime Medicine, Inc. |
| VERV | Verve Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| GTHX | G1 Therapeutics, Inc. |
| HRTX | Heron Therapeutics, Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| CRBU | Caribou Biosciences, Inc. |
| ANNX | Annexon, Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| BEAM | Beam Therapeutics Inc. |
| LIFE | aTyr Pharma, Inc. |
ALLO Ownership FAQ
Who Owns Allogene Therapeutics?
Allogene Therapeutics is owned by institutional shareholders (97.41%), insiders (17.48%), and public (-14.89%). The largest institutional shareholder of Allogene Therapeutics is FMR LLC (18.48% of total shares) and the top mutual fund owner is Kelly Strategic ETF Trust (1.22% of total shares).
Who are the major institutional shareholders of Allogene Therapeutics?
Allogene Therapeutics's major institutional shareholders are FMR LLC, TPG GP A, LLC, BLACKROCK INC., VANGUARD GROUP INC, and STATE STREET CORP. The top five shareholders own together 48.65% of the company's share outstanding.
How many Allogene Therapeutics shareholders are there?
As of Jun 2024, there are 168 institutional shareholders of Allogene Therapeutics.
What percentage of Allogene Therapeutics is owned by FMR LLC?
FMR LLC owns 31.26M shares of Allogene Therapeutics, representing 18.48% of the company's total shares outstanding, valued at $72.83M (as of Jun 2024).
What percentage of Allogene Therapeutics is owned by TPG GP A, LLC?
As of Jun 2024, TPG GP A, LLC holds 18.72M shares of Allogene Therapeutics (ALLO), compromising 11.07% of the company, valued at $43.61M.
What percentage of Allogene Therapeutics is owned by BLACKROCK INC?
BLACKROCK INC is the third largest holder of Allogene Therapeutics. The company owns 16.45M of the company's shares outstanding (worth $38.32M).